30 closest matches · ranked by relevance
Small Cell Lung Cancer · Extensive Stage Lung Cancer · Chemonaive
Primary: Number of Participants Experiencing Dose Limiting Toxicity Regimen A - Phase I — 0; 1; 1 participants
Small Cell Lung Cancer
Primary: Overall Survival — 8.1; 10.6 months — p=<0.01
Carcinoma, Small Cell
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 57 percentage of participants
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants
Extensive-Stage Small Cell Lung Cancer
Primary: Progression Free Survival Rate — 13 percentage of patients with PFS
Small Cell Lung Cancer
Primary: Overall Survival (OS) — 15.5; 13.5 Months — p=0.0040
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Progression-free Survival (PFS) — 5.5; 4.9 months — p=0.17
Small Cell Lung Carcinoma
Primary: Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population — 4.3; 5.2 Months — p=0.0170
Small Cell Lung Cancer
Primary: One-year Survival, The Percentage of Patients Who Are Alive One Year After Completing Protocol Treatment — 54 percentage of participants
Extensive-Stage Small Cell Lung Cancer
Primary: 1-year Survival — 38 percentage of participants
Small Cell Lung Cancer
Primary: Time to Disease Progression - Median Time to Progression and Log-Rank Test — 5.68; 5.62 Months — p=0.10
Lung Cancer, Small Cell
Primary: Overall Response Rate, as Determined by Radiologic Evaluation (Utilizing the World Health Organization [WHO] Criteria), Calculated as the Number of Participants With the…
Small Cell Lung Cancer
Primary: Objective Response Rate — 6 Participants
Extensive Stage Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Progression-free (PF) at 6 Months — 30.2 Percentage of Participants
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Overall Response — 2; 1; 0; 1 Participants
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Small Cell Lung Cancer (SCLC)
Primary: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 4.8…
Extensive Stage Lung Small Cell Carcinoma · Recurrent Lung Small Cell Carcinoma
Primary: Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I) — 25 mg/day
Extensive Stage Small Cell Lung Carcinoma
Primary: Progression Free Survival (PFS) — 5.88; 5.85 Months — p=0.8072
Lung Cancer
Primary: Overall Survival (OS) of Nivolumab + Ipilimumab Versus Placebo In The Global Population — 9.56; 9.17 Months — p=0.3693
Small Cell Lung Carcinoma
Primary: Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy — 10.97; 10.94 months — p=0.3775
Extensive-stage Small Cell Lung Cancer
Primary: Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) — 91 Participants
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Recurrent Lung Non-Small Cell Carcinoma · Stage II Lung Cancer AJCC v8 · Stage III Lung Cancer AJCC v8
Primary: Proportion of Participants With Progression Free Survival (PFS) — 0.6; 0.429 proportion of participants
Extensive Stage Small Cell Lung Carcinoma
Primary: PFS Using RECIST 1.1 — 1.4 months
NSCLC Stage IIIB · NSCLC Stage IV · EGFR Gene Mutation
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 39; 33 Participants
Small Cell Lung Cancer
Primary: Duration of Severe (Grade 4) Neutropenia in Cycle 1 — 0; 4 days — p=<0.0001
Lung Cancer
Primary: Overall Survival — 9.9; 9.1 Months
Lung Cancer
Primary: Number of Grade 3/4 Toxicities Patients Experienced on Maintenance Bevacizumab Following Chemoradiation for Limited Stage - Small Cell Lung Cancer (LS-SCLC) — 2; 1; 1; 1…
Small Cell Lung Cancer · Extensive-stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 1.9; 1.7 Months